Veronique Dinand
Overview
Explore the profile of Veronique Dinand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharma S, Mittal M, Shukla A, Khan J, Dinand V, Saluja D
BMC Cancer
. 2024 Sep;
24(1):1094.
PMID: 39227899
Background: Dysregulated splicing events are a common phenomenon in cancer with the Serine-arginine-rich splicing factor (SRSF) family emerging as pivotal regulators of gene expression, exerting influence over constitutive and alternative...
2.
Banwait D, Arora P, Mahajan A, Dinand V, Jain S, Kalra M, et al.
Pediatr Hematol Oncol
. 2023 Jun;
41(2):163-168.
PMID: 37264813
No abstract available.
3.
Kalra M, Bakhshi S, Singh M, Seth R, Verma N, Jain S, et al.
Pediatr Blood Cancer
. 2022 Nov;
70(2):e30091.
PMID: 36411263
Introduction: The InPOG-HL-15-01, a multicentric prospective study, used a risk-stratified and response-based approach with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) backbone to treat children and adolescents with newly diagnosed Hodgkin...
4.
Mahajan A, Bakhshi S, Singh M, Seth R, Verma N, Jain S, et al.
Indian J Pediatr
. 2022 Jun;
90(8):761-765.
PMID: 35737182
Objective: To evaluate the proportion of patients who received empirical treatment with antitubercular therapy (ATT) prior to the diagnosis of Hodgkin lymphoma (HL) in the first multicentric, prospective study on...
5.
Dinand V, Sachdeva A, Sharma S, Prasad A, Pant D, Sachdev A, et al.
Indian J Med Res
. 2022 Jun;
154(6):843-848.
PMID: 35662089
Background & Objectives: Elevated soluble interleukin-2 receptor (sIL2R) is a diagnostic criterion for haemophagocytic lymphohistiocytosis (HLH). International guidelines propose a 2400 U/ml cut-off or individual laboratory-defined cut-off. However, sIL2R normal...
6.
Mahajan A, Bakhshi S, Seth R, Verma N, Mandal P, Singh M, et al.
J Pediatr Hematol Oncol
. 2022 Mar;
44(4):186-190.
PMID: 35293880
The median age of presentation for Hodgkin lymphoma (HL) is lower in developing countries with a higher proportion under 5 years of age possibly attributable to the high prevalence of...
7.
Jain S, Bakhshi S, Seth R, Verma N, Singh M, Mahajan A, et al.
Leuk Lymphoma
. 2021 Dec;
63(5):1111-1118.
PMID: 34881686
This multi-centric prospective study (InPOG-HL-15-01) assessed epidemiological, clinical and outcome data of advanced stage Hodgkin Lymphoma (IIB, III and IV) in children and adolescents ( = 262). Chemotherapy regimen was...
8.
Mahajan A, Singh M, Bakhshi S, Jain S, Radhakrishnan V, Verma N, et al.
Pediatr Blood Cancer
. 2021 Jul;
68(10):e29219.
PMID: 34291860
Background: Hodgkin lymphoma (HL) in childhood is an eminently curable disease. Excellent outcomes can be achieved even in resource-limited settings and increasingly, the focus is on limiting long-term toxicity. Contemporary...
9.
Talawadekar P, Khanna S, Dinand V, Fernandes P, Deodhar J, Muckaden M
Indian J Palliat Care
. 2020 Oct;
26(Suppl 1):S17-S20.
PMID: 33088080
Introduction: The COVID 19 pandemic has created difficulties for children registered under Children's Palliative Care in Mumbai. 2 hospitals who have started Services last year would like to share their...
10.
Rauf A, Joshi R, Aggarwal N, Agarwal M, Kumar M, Dinand V, et al.
World J Pediatr Congenit Heart Surg
. 2020 Oct;
12(1):61-69.
PMID: 33078664
Background: There is a paucity of literature regarding the association of high oncotic priming solutions for pediatric cardiopulmonary bypass (CPB) and outcomes, and no consensus exists regarding the composition of...